Synthetic oligonucleotides blocking natural degradation of utrophin to treat muscular dystrophy.
Small molecules targeting utrophin mRNA untranslated regions overcome post-transcriptional repression
Duchenne Muscular Dystrophy (DMD) therapy deletes let-7c miRNA binding sites using CRISPR-Cas9 based genome editing and AAV based delivery.
[%brief%]